NCT02561832 2019-02-20
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
AstraZeneca
Phase 1 Terminated
AstraZeneca
Shanghai Jiao Tong University School of Medicine